More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial

(University of Texas M. D. Anderson Cancer Center) A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.